Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Details of the studies that used it for treatment are presented in Table 5.172, 173, 174, 175Studies involving oral isotretinoin, non-melanoma skin cancer, actinic keratoses, and field cancerizationTable 5Author, yearStudy design (n): indicationDose/duration of treatmentResultsHaydey, 1980173Case report (1): multiple keratoacanthomasFrom 2 to 6 mg/kg/day, 16 weeksNo new lesions were observedPeck, 19822Case series (3): multiple BCCMean of 1.5 mg/kg/day, 2.5 to 4 yearsRegression of 9/65 lesions; no new lesions in 2 to 4 yearsLevine, 1984174Case report (1): SCC and multiple keratoacanthomas2 mg/kg/day, 16 weeksRegression of various lesions and reduction of new tumorsPeck, 1987191Case reports (2): multiple BCC2 mg/kg/day, 7 and 8 yearsRegression of 15% of the lesions, decrease in the number of new lesions in the patient exposed to arsenicLippman, 1987175Case series (4): keratoacanthoma and SCCPatient 1: total regression of the keratoacanthoma; 2: partial regression; 3: partial regression of subcutaneous mass; 4 to 70% reduction in SCCKraemer, 1988182Case series (5): xeroderma pigmentosum2 mg/kg/day, 2 years121 tumors before treatmentReduction to 21 tumors in 2 years of treatment Suspension, follow-up for 1 year: 25 tumorsPeck, 1988179Case series (12): BCCMean of 3.1 mg/kg/day, 8 monthsDoses of 0.25 to 1.5 mg/kg/day were ineffectiveMoshell, 1989183Case series (5): xeroderma pigmentosum2 mg/kg/day, 2 years63% reduction in 25 tumorsSuspension: 8 times more tumorsLippman, 1992187Series of cases (32/28): SCC1 mg/kg/day + interferon alfa, 2 monthsPartial response: 68%; total response: 25%Tangrea, 1992180Randomized, placebo-controlled clinical study (951): multiple SCC10 mg/day, 3 yearsNo difference with placeboMajewski, 1994181Case series (4): multiple AK10.4 to 0.5 mg/kg/day + calcitriol, 12 monthsPatient 1: complete response; 2 and 3: 50 to 80% regressionLevine, 1997190Randomized, placebo-controlled clinical study (525): 4 or more BCC or SCCRetinol (25,000) × isotretinoin (5 to 10 mg/day) × placeboNo difference between drugs and placeboFeldman, 2007172Case report (1): multiple keratoacanthomas40 mg/day, followed by acitretin and topical retinoidRegression of some lesionsTroyanova, 2018171Case report (1): epidermodysplasia verruciformis0.33 to 1 mg/kg/day, 18 yearsReduction in the number of SCCIanhez, 2019189Randomized clinical study (60): AK10 mg/day × 0.05% tretinoin creamReduction in the number of AKsSCC, squamous cell carcinoma; BCC, basal cell carcinoma; AK, actinic keratosis.

Source: Field cancerization: multiple actinic keratoses. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Consensus on the use of oral isotretinoin in dermatology: Brazilian Society of Dermatology☆☆☆

Study design awaiting verification · Anais Brasileiros de Dermatologia · 2020

Original publication title

Consensus on the use of oral isotretinoin in dermatology: Brazilian Society of Dermatology☆☆☆

Ediléia Bagatin; Caroline Sousa Costa; Marco Alexandre Dias da Rocha; Fabíola Rosa Picosse; Cristhine Souza Leão Kamamoto; Rodrigo Pirmez; Mayra Ianhez; Hélio Amante Miot

© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Approved and non-approved indications, efficacy and adverse effects of oral isotretinoin in dermatology were presented and critically evaluated.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To communicate the experience and recommendation of Brazilian dermatologists on oral use of the drug in dermatology.

Source: Objective

Abstract: What methods does the paper describe?

Eight experts from five universities were appointed by the Brazilian Society of Dermatology to develop a consensus on indications for this drug. Through the adapted DELPHI methodology, relevant elements were listed and an extensive analysis of the literature was carried out. The consensus was defined with the approval of at least 70% of the experts.

Source: Methods

Abstract: Results

With 100% approval from the authors, there was no doubt about the efficacy of oral isotretinoin in the treatment of acne, including as an adjunct in the correction of scars. Common and manageable common adverse events are mucocutaneous in nature. Others, such as growth retardation, abnormal healing, depression, and inflammatory bowel disease have been thoroughly investigated, and there is no evidence of a causal association; they are rare, individual, and should not contraindicate the use of the drug. Regarding unapproved indications, it may represent an option in cases of refractory rosacea, severe seborrheic dermatitis, stabilization of field cancerization with advanced photoaging and, although incipient, frontal fibrosing alopecia.

For keratinization disorders, acitretin performs better. In the opinion of the authors, indications for purely esthetic purposes or oil control are not recommended, particularly for women of childbearing age.

Source: Results

Abstract: Conclusions

Approved and non-approved indications, efficacy and adverse effects of oral isotretinoin in dermatology were presented and critically evaluated.

Source: Conclusions
Authors’ abstract

Background

Isotretinoin is a synthetic retinoid, derived from vitamin A, with multiple mechanisms of action and highly effective in the treatment of acne, despite common adverse events, manageable and dose-dependent. Dose-independent teratogenicity is the most serious. Therefore, off-label prescriptions require strict criteria.

Objective

To communicate the experience and recommendation of Brazilian dermatologists on oral use of the drug in dermatology.

Methods

Eight experts from five universities were appointed by the Brazilian Society of Dermatology to develop a consensus on indications for this drug. Through the adapted DELPHI methodology, relevant elements were listed and an extensive analysis of the literature was carried out. The consensus was defined with the approval of at least 70% of the experts.

Results

With 100% approval from the authors, there was no doubt about the efficacy of oral isotretinoin in the treatment of acne, including as an adjunct in the correction of scars. Common and manageable common adverse events are mucocutaneous in nature. Others, such as growth retardation, abnormal healing, depression, and inflammatory bowel disease have been thoroughly investigated, and there is no evidence of a causal association; they are rare, individual, and should not contraindicate the use of the drug. Regarding unapproved indications, it may represent an option in cases of refractory rosacea, severe seborrheic dermatitis, stabilization of field cancerization with advanced photoaging and, although incipient, frontal fibrosing alopecia.

For keratinization disorders, acitretin performs better. In the opinion of the authors, indications for purely esthetic purposes or oil control are not recommended, particularly for women of childbearing age.

Conclusions

Approved and non-approved indications, efficacy and adverse effects of oral isotretinoin in dermatology were presented and critically evaluated.

Publication and source details

Original title: Consensus on the use of oral isotretinoin in dermatology: Brazilian Society of Dermatology☆☆☆

Ediléia Bagatin; Caroline Sousa Costa; Marco Alexandre Dias da Rocha; Fabíola Rosa Picosse; Cristhine Souza Leão Kamamoto; Rodrigo Pirmez; Mayra Ianhez; Hélio Amante Miot

Anais Brasileiros de Dermatologia · 2020

⁎ Corresponding author. heliomiot@gmail.com© 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.2020Sociedade Brasileira de Dermatologiahttps://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T14:28:00.583540+00:00

DOI: 10.1016/j.abd.2020.09.001 · PMC7772596